Insulin glargine-aglr

CHEBI:CHEBI_752677

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2589014
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
marketing_start_date
20211217
package_marketing_start_date
20211217
marketing_category
BLA
labeler_name
Eli Lilly and Company
manufacturer_name
Eli Lilly and Company
active_ingredient_strength
100 [iU]/mL
nui
M0011417
pharm_class_epc
Insulin Analog [EPC]
pharm_class
Insulin [CS]
pharm_class_cs
Insulin [CS]
active_ingredient_name
INSULIN GLARGINE
unii
2ZM8CX04RZ
brand_name_suffix
KwikPen
generic_name
Insulin glargine-aglr
brand_name
Rezvoglar KwikPen
brand_name_base
Rezvoglar
product_ndc
0002-8980
application_number
BLA761215
spl_id
a9e95b4c-e280-4bef-a3dd-4907bfad6b4d
package_ndc
0002-8980-05
package_description
5 SYRINGE in 1 CARTON (0002-8980-05) / 3 mL in 1 SYRINGE (0002-8980-01)
spl_set_id
f6af8706-2058-4fe1-99c8-43684c20bfa2
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class